ライフサイエンスコーパス: autonomic failure

1 ation and replicated hypoglycemia-associated autonomic failure.

2 hypoglycemia causing hypoglycemia associated autonomic failure.

3 the pathogenesis of hypoglycemia-associated autonomic failure.

4 F, 13 MSA and 12 non-synucleinopathy-related autonomic failure.

5 inant neuropathy associated with generalized autonomic failure.

6 were not associated with severity of daytime autonomic failure.

7 control subjects, and individuals with pure autonomic failure.

8 with quantitative markers of cardiovascular autonomic failure.

9 nction that is similar to patients with pure autonomic failure.

10 resist the onset of hypoglycemia-associated autonomic failure.

11 l higher in Parkinson's disease than in pure autonomic failure.

12 abetes mellitus and the syndromes of primary autonomic failure.

13 inopathies, multiple system atrophy and pure autonomic failure.

14 relate in a predictable way with severity of autonomic failure.

15 and dementia, sleep disorders, hyposmia and autonomic failure.

16 ccording to the presence or absence of early autonomic failure.

17 ith impairment of baroreflex function due to autonomic failure.

18 the pathogenesis of hypoglycemia-associated autonomic failure.

19 It was indistinguishable from pure autonomic failure.

20 ajor role in causing hypoglycemia-associated autonomic failure.

21 3.2 [7.0-18.6] mU/L), and patients with pure autonomic failure (12.5 [5.6-18.2] mU/L).

22 productive problems, and weight loss suggest autonomic failure, a phenotype that is consistent with t

23 with sympathetic denervation due to primary autonomic failure (AF).

24 omplex multimodal approach to compensate for autonomic failure, alleviate parkinsonism and cerebellar

25 Multiple system atrophy is characterized by autonomic failure along with motor symptoms of parkinson

26 Patients with pure autonomic failure also had very low levels of plasma nor

27 in 19 patients with severe NOH (8 with pure autonomic failure and 11 with multiple-system atrophy).

28 kinson disease or the Lewy body form of pure autonomic failure and 15 controls underwent (18)F-DA dyn

29 opsy from 4 patients with MSA with prominent autonomic failure and 5 patients with no neurological di

30 onsistent phenotype of chronic diarrhea with autonomic failure and a length-dependent axonal, predomi

31 dividuals (7 women, 21-69 years of age) with autonomic failure and gAChR-Ab >100 pM identified betwee

32 tes, are at risk for hypoglycemia-associated autonomic failure and the resultant vicious cycle of rec

33 disease, 54 multiple system atrophy, 20 pure autonomic failure) and 38 controls.

34 nically deficient sympathetic activity (pure autonomic failure), and 15 normal age-matched controls.

35 cerebellar, and mixed), 19 people with pure autonomic failure, and 27 healthy participants.

36 c dysfunction (multiple system atrophy, pure autonomic failure, and baroreflex failure) were compared

37 trophy (MSA) and non-synucleinopathy-related autonomic failure, and examined its relationship with qu

38 ors contribute to asthenia, such as anaemia, autonomic failure, and muscular abnormalities.

39 heral tissues were associated with diarrhea, autonomic failure, and neuropathy.

40 ases, some being indistinguishable from pure autonomic failure, and support the concept that ganglion

41 NTERPRETATION: Patients presenting with pure autonomic failure are at high risk of phenoconverting to

42 d ratio 1.02, P = 0.001); and (vi) degree of autonomic failure as measured by a validated composite a

43 Autonomic dysfunction was defined as autonomic failure at autonomic function testing or 2 of

44 and MSA-C are similar and severe symptomatic autonomic failure at diagnosis is associated with worse

45 negative, normal autonomic tests), and pure autonomic failure (COVID-19 negative, abnormal autonomic

46 ich is usually beneficial in primary chronic autonomic failure, does not seem to be beneficial in the

47 ing; festination or retropulsion; concurrent autonomic failure; dramatic response to anticholinergics

48 es and repeat testing indicated worsening of autonomic failure during the disease course.

49 g exercise would prevent exercise-associated autonomic failure (EAAF).

50 In MSA early autonomic failure, female gender, older age of onset, a

51 (median +/- interquartile range) and had had autonomic failure for 5 +/- 7 years.

52 In those with MSA who had central autonomic failure, GH concentrations were unchanged (MSA

53 COVID were comparable with those in the pure autonomic failure group.

54 's disease, multiple system atrophy and pure autonomic failure groups all had lower cerebrospinal flu

55 ine (NAC), prevented hypoglycemia-associated autonomic failure (HAAF) and impaired activation of vent

56 s the key feature of hypoglycemia-associated autonomic failure (HAAF) and, thus, the pathogenesis of

57 Hypoglycemia-associated autonomic failure (HAAF) constitutes one of the main cli

58 The concept of hypoglycemia-associated autonomic failure (HAAF) in diabetes posits that recent

59 a phenomenon termed hypoglycemia-associated autonomic failure (HAAF) in diabetes.

60 Hypoglycemia-associated autonomic failure (HAAF) occurs commonly in patients wit

61 l condition known as hypoglycemia-associated autonomic failure (HAAF) that may occur in patients with

62 his effect, known as hypoglycemia-associated autonomic failure (HAAF), occurs in diabetic patients as

63 poglycemia, known as hypoglycemia-associated autonomic failure (HAAF), occurs in diabetic patients in

64 Hypoglycemia-associated autonomic failure (HAAF)-reduced autonomic (including ad

65 responses, known as hypoglycemia-associated autonomic failure (HAAF).

66 Approximately 50% of patients with primary autonomic failure have supine hypertension.

67 rthostatic hypotension and confirmed chronic autonomic failure in 31 (4.8%) patients.

68 e neurodegenerative disease characterized by autonomic failure in addition to various combinations of

69 , the key feature of hypoglycemia-associated autonomic failure in diabetes, in humans.

70 , the key feature of hypoglycemia-associated autonomic failure in diabetes, in humans.

71 t hypoglycemia-associated neuroendocrine and autonomic failure in healthy humans.

72 f hypoglycemia-associated neuroendocrine and autonomic failure in healthy humans.

73 impaired autonomic synaptic transmission and autonomic failure in mice implicates an antibody-mediate

74 favourable course than PSP-P, and that early autonomic failure in MSA is associated with shorter surv

75 tonomic failure, multiple system atrophy, or autonomic failure in Parkinson disease), orthostatic hyp

76 re likely to develop hypoglycemia-associated autonomic failure in response to recurrent hypoglycemic

77 inant cerebellar involvement) in eight, pure autonomic failure in two and Parkinson's disease in one.

78 ial as a therapy for hypoglycemia-associated autonomic failure in type 1 diabetes.

79 unifying concept of hypoglycemia-associated autonomic failure in type 1 diabetes.

80 ography and a human neurological model (pure autonomic failure), in which peripheral autonomic denerv

81 This sleep-related hypoglycemia-associated autonomic failure, in the context of imperfect insulin r

82 cy) is a rare congenital disorder of primary autonomic failure, in which neurotransmitters NE and epi

83 Parkinson's disease and pure autonomic failure involve differential dopaminergic vers

84 Autonomic failure is an integral component of diabetic n

85 Development of autonomic failure is associated with more rapid disease

86 assess whether such hypoglycemia-associated autonomic failure is due to actual brain damage, male Sp

87 r characterised by a variable combination of autonomic failure, levodopa-unresponsive parkinsonism, c

88 neurodegenerative disorder characterised by autonomic failure, manifested as orthostatic hypotension

89 Thus, hypoglycemia-associated autonomic failure may be due in part to a relative exces

90 In chronic autonomic failure (pure autonomic failure, multiple system atrophy, or autonomic

91 out SH (PD - SH, n = 19), patients with pure autonomic failure (n = 8), and controls (n = 16).

92 h the multiple system atrophy (n=5) and pure autonomic failure (n=4) groups, all initial pressures we

93 in the USA, and the effects of phenotype and autonomic failure on prognosis.

94 Patients with pure autonomic failure or parkinsonism and sympathetic neuroc

95 0.001), cerebral blood flow (p = 0.002) and autonomic failure (p = 0.035) scores.

96 static hypotension (OH) (PD+OH) or with pure autonomic failure (PAF) have markedly decreased myocardi

97 The current research challenge in pure autonomic failure (PAF) lies in identifying specific bio

98 the clinical features of patients with pure autonomic failure (PAF) preceding phenoconversion that c

99 Pure autonomic failure (PAF) presents with progressive autono

100 In the pure autonomic failure (PAF), alpha-synuclein (alpha-Syn) pat

101 s with multiple system atrophy (MSA) or pure autonomic failure (PAF), we studied the effect of oral y

102 DLB), multiple system atrophy (MSA) and pure autonomic failure (PAF).

103 stem atrophy (MSA), and 8 patients with pure autonomic failure (PAF).

104 ion (PD+OH, PD-No-OH); in patients with pure autonomic failure (PAF, a Lewy body disease without park

105 LB], multiple system atrophy [MSA], and pure autonomic failure [PAF]) is an urgent unmet need.

106 features of the disease include progressive autonomic failure, parkinsonism, and cerebellar ataxia l

107 Compared with pure autonomic failure patients, patients with long COVID had

108 e small group of patients retaining the pure autonomic failure phenotype had very low plasma norepine

109 neurodegenerative disorder with symptoms of autonomic failure plus parkinsonism, cerebellar ataxia,

110 In chronic autonomic failure (pure autonomic failure, multiple syst

111 2 weeks later the autonomic failure recurred but again responded to treatm

112 SAS and QASAT autonomic failure scores worsened in controls.

113 e system atrophy had younger age at onset of autonomic failure, severe bladder/bowel dysfunction, pre

114 Participants with severe symptomatic autonomic failure (symptomatic orthostatic hypotension,

115 rtain disorders, such as the primary chronic autonomic failure syndromes; it can complicate a variety

116 een PAF, MSA and non-synucleinopathy-related autonomic failure to aid early diagnosis and recruitment

117 no signs of central neurodegeneration (pure autonomic failure), two with parkinsonism responsive to

118 Autonomic failure was severe: CASS was 7.2+/-2.3 (maximu

119 een shown to prevent hypoglycemia-associated autonomic failure, we hypothesized that OR blockade duri

120 nts with multiple systems atrophy (MSA) with autonomic failure, we sought to test the hypothesis that

121 nts with a known or provisional diagnosis of autonomic failure were excluded from analysis.

122 One hundred patients who presented with pure autonomic failure were recruited at 5 medical centers in

123 etrospective samples from patients with pure autonomic failure who later developed PD or MSA.

124 arkers that predict which patients with pure autonomic failure will develop Parkinson disease, dement

125 attern of severe and progressive generalised autonomic failure with severe adrenergic and sudomotor f

126 serum in healthy people and those with pure autonomic failure (with peripheral lesions), but not in

127 f widespread sympathetic and parasympathetic autonomic failure, with significant improvements after i

128 Of the 83 cases of MSA, 42 (53.2%) had autonomic failure within 2 years of disease onset.

129 omic failure (PAF) presents with progressive autonomic failure without other neurological features.

130 The presence of autonomic failure worsens prognosis in the diabetic stat